The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealing

10 Jan 2018 17:09

RNS Number : 5371B
Amphion Innovations PLC
10 January 2018
 

 

AMPHION INNOVATIONS PLC

 ("Amphion" or "the Company")

 

Directors' Dealings

London and New York, 10 January 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 5 January 2018 it granted options over ordinary shares in the Company ("Options") to certain of its directors as follows:

Director

Amount

Strike Price

Vesting

Richard Mansell-Jones

563,000

1.94 pence

Over one year starting as of 1 August 2017

Miroslaw Izienicki

375,000

1.94 pence

Over one year starting as of 1 August 2017

 

All Options commence vesting backdated from 1 August 2017.

 

The strike price is based on the closing price on 4 January 2018, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme was approved as a part of the Company's Annual General Meeting.

 

In addition to the above Options allocation, the Company has issued 799,562 ordinary shares in the Company ("New Ordinary Shares"), representing 0.38% of the enlarged issued share capital, to certain of its Board members (current and former) in payment of directors' fees due them. The issue of Ordinary Shares is calculated based on the closing mid-market price for the five days leading up to the close on 4 January 2018. Following this issue the current directors' shareholdings in the Company are as follows:

 

Director

Number of New Ordinary Shares

Total Shareholding

Percentage ofVoting Rights

Miroslaw Izienicki

193,791

795,280

0.379%

Richard Mansell-Jones

558,896

4,344,426

2.069%

Gerard Moufflet (former director)

46,875

1,320,833

0.629%

Admission of the 799,562 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 17 January 2018. Following the issue and allotment of the New Ordinary Shares, the total issued share capital of the Company will increase to 209,975,450 ordinary shares with each share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Mansell-Jones

2

Reason for the notification

a)

Position/status

Chairman and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Nature of the transaction

Richard Mansell-Jones has received new Ordinary Shares in lieu of fees

c)

Price(s) and volume(s)

558,896 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Miroslaw Izienicki

2

Reason for the notification

a)

Position/status

Non-executive Director and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Nature of the transaction

Miroslaw Izienicki has received new Ordinary Shares in lieu of fees

c)

Price(s) and volume(s)

193,791 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Mansell-Jones

2

Reason for the notification

a)

Position/status

Chairman and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.94p

563,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Miroslaw Izienicki

2

Reason for the notification

a)

Position/status

Non-executive Director and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.94p

375,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan

Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Freddy Crossley / Ryan McCarthy (Corporate Finance)

Charlie Leigh-Pemberton (Corporate Broking)

Northland Capital Partners Limited (Joint Corporate Broker)

Tel: +44 (0)20 3861 6625

Patrick Claridge / David Hignell (Corporate Finance)

John Howes (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or

Anna Dunphy / Paul McManus

amphion@walbrookpr.com

 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDBLFFVFFBBBV
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.